Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96823 | 0.82 | TDP1 (0.61) | TDP1ERN1ALDH1A1KDM4EHTT | |
| SCHEMBL31171177 | 0.82 | TDP1 (0.61) | TDP1ERN1ALDH1A1KDM4EHTT | |
| SCHEMBL20074265 | 0.79 | CDK4 (0.37) | ALDH1A1HTTSMN1; SMN2LMNANPC1 | |
| SCHEMBL4363014 | 0.78 | ERN1 (0.46) | TDP1ERN1ALDH1A1KDM4ELMNA | |
| SCHEMBL29957006 | 0.78 | ERN1 (0.46) | TDP1ERN1ALDH1A1KDM4ELMNA | |
| SCHEMBL16958857 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HTTSMN1; SMN2NPC1MAPT | |
| SCHEMBL16961502 | 0.77 | NPC1 (0.40) | HTTSMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL5404806 | 0.77 | NFE2L2 (0.36) | HTTSMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL65723 | 0.76 | ERN1 (0.56) | ERN1ALDH1A1KDM4EPTPN1NFE2L2 | |
| Water SCHEMBL28915146 | 0.76 | ERN1 (0.45) | TDP1ERN1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496215-A | Polyhydroxylated onium derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-08-16 | — | — | CN | claimed |
| CN-118344299-A | Triazole chalcone compound, and preparation method and application thereof | 延边大学 | 2024-07-16 | — | — | CN | claimed |
| CN-117624148-A | Polyhydroxy sulfonium salt derivative with disubstituted benzene ring, preparation method and medical application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | claimed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | claimed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | claimed |
| US-20210169966-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2021-06-10 | — | — | US | claimed |
| EP-3749365-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | Ohio State Innovation Foundation (US) | 2020-12-16 | — | — | EP | claimed |
| WO-2019148194-A2 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-01 | — | — | WO | claimed |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4703361-A1 | PYRIDAZINONE TRPC4/5 INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4648766-A1 | PI3K INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Relay Therapeutics, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| EP-1182194-A1 | PERNASAL PREPARATIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6350749-B1 | SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| CN-1290249-A | Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
| EP-1057812-A1 | AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0950418-A2 | Composition for preventing or treating ischemic disease | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0339417-A1 | 3-Cyano-4-phenyl-pyrroles | BAYER AG (DE) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | TDP1 2328/4885ERN1 379/4885ALDH1A1 4550/4885 |
| US-20210169966-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | TDP1 3097/4885ERN1 1946/4885ALDH1A1 4853/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | TDP1 3049/4885ERN1 1903/4885ALDH1A1 4851/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | TDP1 3284/4885ERN1 437/4885ALDH1A1 1259/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | TDP1 3049/4885ERN1 1903/4885ALDH1A1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.